Uncovering behind-the-scenes challenges in bringing gene therapies to market
Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.
Read MoreClinically Speaking: Boosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read MoreEvernorth Announces Industry-First Financial Guarantee For GLP-1 Spend
EncircleRx solution now includes financial predictability for health plan sponsors to help expand access for appropriate patients.
Read MoreEasing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read MoreStudy: Progression of cardiodiabesity increases care utilization and costs
The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.
Read More